Nanobiotix (NASDAQ:NBTX) Shares Gap Up – What’s Next?

Posted by Don Miller on Sep 25th, 2026

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s stock price gapped up prior to trading on Wednesday. The stock had previously closed at $35.15, but opened at $36.05. Nanobiotix shares last traded at $35.7960, with a volume of 7,275 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NBTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Leerink Partners raised their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, June 4th. Finally, Guggenheim assumed coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Check Out Our Latest Stock Report on Nanobiotix

Nanobiotix Stock Down 5.1%

The business has a fifty day simple moving average of $38.82 and a 200-day simple moving average of $37.39.

Nanobiotix (NASDAQ:NBTX – Get Free Report) last announced its earnings results on Thursday, September 24th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. The business had revenue of $3.17 million for the quarter, compared to the consensus estimate of $1.73 million. On average, equities analysts forecast that Nanobiotix S.A. – Sponsored ADR will post -0.16 EPS for the current year.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.